SCHEMBL5769573

SCHEMBL5769573

Cc1nc(-c2n[nH]c3c(Cl)cccc23)sc1-c1cccc(O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 1/20 0.39
CHEK1 O14757 1/20 0.37
FLT3 P36888 1/20 0.37
PLK3 Q9H4B4 1/20 0.37
HSD17B1 P14061 4/20 0.37
HSD17B2 P37059 3/20 0.37
PRKAB2 O43741 1/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAA1 Q13131 1/20 0.36
PRKAG3 Q9UGI9 1/20 0.36
PRKAG2 Q9UGJ0 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
COMT P21964 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872883 0.85 ADORA2A (0.42) CHEK1FLT3PLK3SMN1; SMN2RAB9A
SCHEMBL5773591 0.83 JAK2 (0.47) F2RL3CHEK1HSD17B1HSD17B2SMN1; SMN2
SCHEMBL5873225 0.72 KDM4E (0.49) SMN1; SMN2KDM4EALDH1A1MAPTTRPM8
SCHEMBL12754295 0.71 HSD17B1 (0.54) F2RL3HSD17B1HSD17B2SMN1; SMN2KDM4E
SCHEMBL4025987 0.70 CHEK1 (0.54) CHEK1FLT3PLK3
SCHEMBL5769801 0.68 ITK (0.48) FLT3SMN1; SMN2KDM4EALDH1A1RAB9A
SCHEMBL5772793 0.67 JAK2 (0.43) CHEK1FLT3SMN1; SMN2KDM4EALDH1A1
SCHEMBL4034365 0.67 CHEK1 (0.50) CHEK1FLT3PLK3JAK3
SCHEMBL5872907 0.65 RPA1 (0.44) SMN1; SMN2KDM4EALDH1A1LMNARAB9A
SCHEMBL13122682 0.65 CHEK1 (0.63) CHEK1FLT3PLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664040-A1 GYRASE INHIBITORS PFIZER INC. (US) 2006-06-07 EP disclosed
US-6984652-B2 Gyrase inhibitors WARNER-LAMBERT COMPANY LLC (US) 2006-01-10 US disclosed
US-20050250823-A1 Gyrase inhibitors YAGER KRAIG 2005-11-10 US disclosed
WO-2005026162-A1 GYRASE INHIBITORS PFIZER INC. (US) 2005-03-24 WO disclosed
US-20050054697-A1 Gyrase inhibitors PFIZER INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054697-A1 Gyrase inhibitors TOP1, TOP2A, TOP2B F2RL3 3522/4885CHEK1 54/4885FLT3 1967/4885
US-20050250823-A1 Gyrase inhibitors TOP1, TOP2A, TOP2B F2RL3 3522/4885CHEK1 54/4885FLT3 1967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.